Published in Drug Law Weekly, November 14th, 2006
The published article "Dextromethorphan and Quinidine in Adult Patients with Uncontrolled Painful Diabetic Peripheral Neuropathy: A 29-Day, Multicenter, Open-Label, Dose-Escalation Study" indicates that the investigational new drug was well tolerated up to the highest target dose (60 mg dextromethorphan and 60 mg of quinidine dosed twice per day).
The open label trial, conducted at five U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.